ClinicalTrials.gg
RecruitingNCT07654972Updated Oct 15, 2026

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

A Phase 1 interventional study of LY4174794 and LY4174794 in Obesity and Overweight, sponsored by Eli Lilly and Company. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 15, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 53 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Planned enrollment
90th of 117
116 · median 267
Started
2026
with 24 others
Phase 1
40 of 118
8 open now
Primary completion
2029-04
later than 47 of 52 live
Registered
103rd of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 90th largest by planned enrollment of the 117 interventional ones that give a count, is one of 25 that started in 2026, is one of 40 in phase 1, reaches primary completion later than 47 of the 52 other live ones, and was the 103rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,059 are open to participants now.

Browse Obesity studies →

Open to participants now

30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Who these studies take

Of the 1,350 Obesity studies recruiting now, 382 (28%) set no upper age limit and 864 (64%) stop at 75 or younger; 168 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.

Participation in this study will last about 30 to 39 weeks (7 to 10 months).

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy with no comorbidities related to (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
  • Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
  • Have had a self-reported stable weight for 3 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
  • Is an individual of (IOCBP)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Part A: LY4174794

    Participants will receive LY4174794 administered subcutaneously (SC).

    Drug: LY4174794 · Drug: Placebo

  • Experimental
    Part B: LY4174794

    Participants will receive LY4174794 administered SC.

    Drug: LY4174794 · Drug: Placebo

  • Placebo comparator
    Part A & B: Placebo

    Participants will receive placebo administered SC.

    Drug: Placebo

  • Experimental
    Part C: LY4174794

    Participants will receive LY4174794 administered intravenously (IV).

    Drug: LY4174794

Interventions

  • DrugLY4174794

    Administered SC.

  • DrugLY4174794

    Administered IV.

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline through end of the Follow-up (Week 25)

  2. Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline through end of the Follow-up (Week 33)

Secondary outcomes

  1. Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4174794

    Time frame: Predose on day 1 through end of the Follow-up Period (Week 25)

  2. Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794

    Time frame: Predose on day 1 through end of the Follow-up Period (Week 25)

  3. Part B: PK: Maximum Observed Drug Concentration (Cmax) of LY4174794

    Time frame: Predose on day 1 through end of the Follow-up Period (Week 33)

  4. Part B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794

    Time frame: Predose on day 1 through end of the Follow-up Period (Week 33)

07

Study locations

1 of 3 sites recruiting
  • ICON Early Phase Services, LLC
    San Antonio, Texas 78232, United States
    Recruiting
    • · Contact(210) 225-5437
    • Cassandra Key · Principal investigator
  • ICON Early Phase Services, LLC
    Salt Lake City, Utah 84124, United States
    Not yet recruiting
    • · Contact801-261-3341
    • Ahad Sabet · Principal investigator
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
    Not yet recruiting
    • · Contact+65 6413 9811
    • Jennifer Boon Wee · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2029, 34 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 34 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 17, 2026
StartActual
Jun 24, 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
108→116
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Enrollment 108→116
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07654972
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jun 24, 2026
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion